OncoMatch/Clinical Trials/NCT05674305
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
Is NCT05674305 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Radiotherapy and Cisplatin for nasopharyngeal carcinoma.
Treatment: Radiotherapy · Cisplatin — The goal of this multicenter randomized non-inferior study is to compare radiotherapy alone versus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA drop to undetectable level after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: the omission of concurrent chemotherapy is safe in the relatively good prognostic patients identified by the response of EBV DNA. Participants will be randomized to either radiotherapy alone or the standard treatment concurrent chemoradiotherapy if their EBV DNA decrease to undetectable level post first cycle of neoadjuvant chemotherapy and don't rebound in the second and third cycle.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Cannot have received: chemotherapy
Cannot have received: targeted therapy
Lab requirements
Blood counts
HGB ≥90 g/L, WBC ≥4×10^9 /L, PLT ≥100×10^9 /L
Kidney function
serum creatinine <1x ULN
Liver function
ALT, AST < 1.5x ULN; total bilirubin <1.0x ULN
Hemoglobin (HGB) ≥90 g/L, white blood cell (WBC) ≥4×10^9 /L, platelet (PLT) ≥100×10^9 /L. Liver function: ALT, AST < 1.5x ULN, total bilirubin <1.0x ULN. Renal function: serum creatinine <1x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05674305 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages